Targeted therapies: Endothelin receptor antagonists

Advances in the Management of Pulmonary Arterial Hypertension

Volumn , Issue , 2013, Pages 65-73

  Smith, Kimberly A ^a   Fraidenburg, Dustin R ^a   Yuan, Jason X J ^a,b,c  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b The American Physiological Society   (United States)

^c AMERICAN HEART ASSOCIATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84921944188     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.2217/EBO.13.239     Document Type: Chapter

References (20)

1. Mandegar M, Fung YC, Huang W, Remillard CV, Rubin LJ, Yuan JX. Cellular and molecular mechanisms of pulmonary vascular remodeling: role in the development of pulmonary hypertension. Microvasc. Res. 68, 75-103 (2004).
2. Pauwaa S, Machado RF, Desai AA. Survival in pulmonary arterial hypertension: a brief review of registry data. Pulm. Circ. 1, 430-431 (2011).
3. Stamm JA, Risbano MG, Mathier MA. Overview of current therapeutic approaches for pulmonary hypertension. Pulm. Circ. 1, 138-159 (2011).
4. Shao D, Park JE, Wort SJ. The role of endothelin-1 in the pathogenesis of pulmonary arterial hypertension. Pharmacol. Res. 63, 504-511 (2011).
5. Hassoun PM, Thappa V, Landman MJ, Fanburg BL. Endothelin 1: mitogenic activity on pulmonary artery smooth muscle cells and release from hypoxic endothelial cells. Proc. Soc. Exp. Biol. Med. 199, 165-170 (1992).
6. Stelzner TJ, O'Brien RF, Yanagisawa M et al. Increased lung endothelin-1 production in rats with idiopathic pulmonary hypertension. Am. J. Physiol. 262, L614-L620 (1992).
7. Rubin LJ. Endothelin receptor antagonists for the treatment of pulmonary artery hypertension. Life Sci. 91, 517-521 (2012).
8. Takuwa Y, Kasuya Y, Takuwa N et al. Endothelin receptor is coupled to phospholipase C via a pertussis toxin-insensitive guanine nucleotide-binding regulatory protein in vascular smooth muscle cells. J. Clin. Invest. 85, 653-658 (1990).
9. Dupuis J, Goresky CA, Fournier A. Pulmonary clearance of circulating endothelin-1 in dogs in vivo: exclusive role of ETB receptors. J. Appl. Physiol. 81, 1510-1515 (1996).
10. Giaid A, Yanagisawa M, Langleben D et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N. Engl. J. Med. 328, 1732-1739 (1993).
11. Cacoub P, Dorent R, Nataf P et al. Endothelin-1 in the lungs of patients with pulmonary hypertension. Cardiovasc. Res. 33, 196-200 (1997).
12. B receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 165, 398-405 (2002).
13. O'Callaghan DS, Savale L, Yaici A et al. Endothelin receptor antagonists for the treatment of pulmonary arterial hypertension. Expert Opin. Pharmacother. 12, 1585-1596 (2011).
14. Galie N, Olschewski H, Oudiz RJ et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 117, 3010-3019 (2008).
15. Spence R, Mandagere A, Richards DB, Magee MH, Dufton C, Boinpally R. Potential for pharmacokinetic interactions between ambrisentan and cyclosporine. Clin. Pharmacol. Ther. 88, 513-520 (2010).
16. Channick RN, Simonneau G, Sitbon O et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 358, 1119-1123 (2001).
17. Rubin LJ, Badesch DB, Barst RJ et al. Bosentan therapy for pulmonary arterial hypertension. N. Engl. J. Med. 346, 896-903 (2002).
18. Galie N, Rubin L, Hoeper M et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 371, 2093-2100 (2008).
19. Iglarz M, Binkert C, Morrison K et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 327, 736-745 (2008).
20. Rubin L, Pulido T, Channick R et al. Effect of macitentan on morbidity and mortality in pulmonary arterial hypertension (PAH): results from the SERAPHIN trial. Chest 142, 1026A (2012).